XENE Stock Up as Azetukalner Meets Goal in Focal Onset Seizures Study

Core Insights - Shares of Xenon Pharmaceuticals (XENE) increased by 49.6% following the announcement of positive top-line data from the phase III X-TOLE2 study for azetukalner, aimed at treating focal onset seizures (FOS) [1] Study Results - The X-TOLE2 study assessed the efficacy, safety, and tolerability of azetukalner at doses of 15 mg and 25 mg, administered with food as an add-on treatment for FOS patients [2] - The study achieved its primary endpoint, demonstrating a median percent change (MPC) in monthly FOS frequency from baseline to week 12 for both doses compared to placebo [2] - The placebo-adjusted MPC for the 25 mg group was -42.7%, an improvement over the -34.6% observed in the earlier phase IIb X-TOLE study [3] - Azetukalner was generally well-tolerated, exhibiting a safety profile consistent with previous studies [3] Future Plans - Xenon intends to submit a new drug application (NDA) to the FDA for azetukalner to treat FOS in Q3 2026 [3][7] - The company is also conducting the phase III X-TOLE3 study for azetukalner in FOS, which is currently enrolling patients to support regulatory submissions in markets outside the U.S. [6] Competitive Position - If approved, azetukalner would be the only KV7 potassium channel opener available for epilepsy treatment, supported by its favorable safety profile and differentiated mechanism [8] - Besides FOS, azetukalner is being developed for other neurological disorders, including major depressive disorder (MDD) and bipolar depression (BPD) [9] Clinical Development - Xenon is conducting two phase III studies, X-NOVA2 and X-NOVA3, for azetukalner in MDD, with top-line data from X-NOVA2 expected in the first half of 2027 [10] - The first of two phase III studies, X-CEED, for azetukalner in BPD is also ongoing [10] Stock Performance - Over the past six months, Xenon's shares have increased by 68.6%, outperforming the industry average increase of 14.3% [4]